Raloxifene HCL + Raloxifene HCL + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoporosis, Postmenopausal
Conditions
Osteoporosis, Postmenopausal
Trial Timeline
Nov 1, 1994 → Sep 1, 1999
NCT ID
NCT00670319About Raloxifene HCL + Raloxifene HCL + Placebo
Raloxifene HCL + Raloxifene HCL + Placebo is a phase 3 stage product being developed by Eli Lilly for Osteoporosis, Postmenopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00670319. Target conditions include Osteoporosis, Postmenopausal.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00670319 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoporosis, Postmenopausal